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Abstract: This observational study compared uptake of infant
prevention of mother-to-child transmission of HIV services pre/post
implementation of Option B+ in Lilongwe, Malawi. There were 845
(pre) and 998 (post) births. Post-B+, infants had longer median
predelivery maternal antiretroviral therapy {62 days [interquartile
range (IQR): 38–94] pre-B+ vs. 95 days [IQR: 61–131] post-B+;
P , 0.0001} and improved polymerase chain reaction testing (82.0%
vs. 86.5%; P = 0.01) at younger median age [7.6 weeks (IQR: 6.6–
10.9) vs. 6.9 (IQR: 6.4–8.1); P , 0.0001]. Proportion testing
polymerase chain reaction positive decreased (4.6% vs. 2.6%; P =
0.03). Proportion of HIV-infected infants starting antiretroviral therapy
(75% vs. 77.3%) and age at initiation [19.7 weeks (IQR: 15.4–31.1)
vs. 16 (IQR: 13.3–17.9)] remained unchanged. These findings suggest
modest improvements in infant care with Option B+.
Key Words: HIV, PMTCT, Option B+, Africa, antiretroviral, early
infant diagnosis, Malawi
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INTRODUCTION
Antiretroviral medications are highly effective for pre-
venting mother-to-child transmission of HIV (PMTCT). How-
ever, in 2013, over 240,000 children worldwide were infected
with HIV; the majority in sub-Saharan Africa.1 Incremental
losses along the PMTCT cascade have been a significant
challenge to optimizing PMTCT outcomes.2–5 Furthermore,
a majority of HIV-exposed infants do not receive HIV testing,
contributing to inadequate antiretroviral therapy (ART) cover-
age for children that is estimated to be 24%.1,6
In July 2011, the Malawi Ministry of Health (MOH)
implemented Option B+ (B+), an innovative approach to
improve uptake of PMTCT.7,8 In addition to offering lifelong
ART to all pregnant and breastfeeding women, HIV-exposed
infant care was integrated with maternal ART follow-up to
improve retention.9 Infants receive 6 weeks of nevirapine
starting at birth, early infant HIV DNA polymerase chain
reaction (PCR) diagnosis using dried blood spots after 6
weeks of age and clinical follow-up until determination of
final infection status.10,11
Several studies have examined the impact of B+ on the
PMTCT cascade, particularly uptake and retention of women
on ART.12,13 However, little attention has focused on infant
outcomes,14–18 particularly HIV diagnosis, transmission, and
treatment.19,20 We assessed the impact of the change to B+ on
the infant PMTCT cascade, by comparing service uptake pre-
and post-B+ implementation (post-B+) at 2 large health
centers in urban Lilongwe.
METHODS
Study Design
A pre/poststudy using routinely collected program data of
infants born to women enrolled in the PMTCT program during
two 18-month periods pre-B+ (October 2009–March 2011) and
post-B+ (October 2011–March 2013). Our primary objective
was to compare uptake of early infant HIV diagnosis (EID) with
Received for publication November 4, 2014; accepted March 27, 2015.
From the *Baylor College of Medicine International Pediatric AIDS Initiative at
Texas Children’s Hospital, Houston, TX; †Baylor College of Medicine-
Abbott Fund Children’s Clinical Center of Excellence, Lilongwe, Malawi;
‡UNC Project, Lilongwe, Malawi; §University of North Carolina School of
Medicine, Chapel Hill, NC; kDepartment of Pediatrics, Epidemiology Center,
Baylor College of Medicine, Houston, TX; ¶Department of HIV and AIDS,
Ministry of Health, Lilongwe, Malawi; #ICAP-Columbia University, Mail-
man School of Public Health, New York, NY; and **College of Physicians
and Surgeons, Columbia University, New York, NY.
This study was made possible through the Tingathe program supported by
USAID cooperative agreement number 674-A-00-10-00093-00. M.H.K.
was supported by the Fogarty International Center of the National
Institutes of Health under award number K01 TW009644. Data analysis
was provided by the Design and Analysis Core of the Baylor-UT Houston
Center for AIDS Research, an NIH-funded program numbered P30-
AI36211.
Presented in part at the 21st Conference on Retrovirology and Opportunistic
Infections, Poster 803, March 3–6, 2014, Boston, MA.
The authors have no conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF
versions of this article on the journal’s Web site (www.jaids.com).
M.H.K. and S.A. conceived and designed the study, were responsible for
study coordination and data management, helped analyze data, interpreted
findings, and wrote the article. E.J.A. reviewed the study protocol,
provided guidance on the conduct of the study, helped interpret findings,
helped write the article. M.C.H., F.C., P.N.K., and M.E.P. reviewed the
study protocol, provided guidance on the conduct of the study, and
critically reviewed the article for important intellectual content. C.N. and
X.Y. assisted in statistical analysis, interpretation, and article writing. All
authors have read and approved the final article.
The contents are the responsibility of the authors and do not necessarily
reflect the views of the funders, including the National Institutes of
Health, USAID, and the US Government.
Correspondence to: Maria H. Kim, MD, Baylor College of Medicine,
Department of Pediatrics, Section of Retrovirology and Global Health,
1102 Bates FC 630, Houston TX 77030. e-mail: (mhkim@bcm.edu).
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
J Acquir Immune Defic Syndr  Volume 70, Number 1, September 1, 2015 www.jaids.com | 99
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
HIV DNA PCR testing (PCR test) and infant ART initiation
pre- and post-B+. We also compared uptake of maternal/infant
ART/antiretroviral medications for PMTCT and duration of
maternal ART predelivery and evaluated maternal factors
associated with failure to obtain an infant PCR test.
Study Setting, Patient Population, and
Routine PMTCT Program Services
Program data were available for Area 25 and Kawale, 2
large urban communities in Lilongwe, Malawi. All PMTCT
care including the Tingathe community health worker (CHW)
support was provided in accordance with WHO and Malawi
MOH guidelines as has been previously.8,21–26 To align
support services with the policy of ART for all HIV-
infected pregnant women (B+), CHWs were trained on the
new national guidelines.8 In compliance with national policy
change to B+, HIV-exposed infant follow-up was integrated
with maternal ART follow-up. Other than these modifica-
tions, service activities were unchanged.
Statistical Analysis
Service uptake along the infant PMTCT cascade was
compared between infants of women enrolled pre-B+ and
post-B+. Wilcoxon rank-sum test was used for continuous
and x2 test or Fisher exact test for categorical variables.
Logistic regression was used to identify maternal
factors associated with failure to obtain an infant PCR test
among births post-B+. We considered the following 5 factors:
maternal age, trimester of pregnancy, HIV status at enroll-
ment, ART initiation, and partner disclosure. We excluded
women who transferred out before infant PCR. Univariate
analysis was followed by multiple logistic regression to
simultaneously evaluate the effects of these factors on failure
to obtain infant PCR. Two-way interactions were not
significant and therefore not retained in the model. The final
model was checked by goodness-of-fit and influential statis-
tics. We reported crude and adjusted odds ratio (OR) and 95%
confidence intervals (CIs) to evaluate the associations
between covariates and the outcome with and without
adjustment of covariates, respectively.
Additionally, we examined the association between
maternal ART outcome 6 months after initiation and failure to
obtain an infant PCR test among women newly initiating
ART post-B+. Only infants born to women enrolled while
pregnant were included. Women who transferred out before
infant PCR were excluded. We used Fisher exact test to
compare infant PCR completion rates among the maternal
6-month ART outcome categories, and univariate logistic
regression was performed to obtain OR estimates.
A P , 0.05 was considered statistically significant, and
SAS software version 9.3 (SAS Institute, Cary, NC) was used
for all analyses.
Ethics Statement
The National Health Sciences Research Committee of
Malawi and the Baylor College of Medicine Institutional
Review Board approved the study. Data were deidentified
before analysis.
RESULTS
There were 845 (pre) and 998 (post) infants born to
women enrolled in the PMTCT program. Post-B+, a greater
proportion of infants were born to women who enrolled
earlier in pregnancy, were known to be HIV-infected (30.2%
vs. 48.4%; P , 0.0001), and on ART at enrollment (20.6%
vs. 32.6%; P, 0.0001) (Table 1). There was no change in the
proportion of mothers and infants who newly received
antiretrovirals for PMTCT pre- and post-B+. However,
among women newly initiating ART, median duration on
ART before delivery was significantly longer post-B+ (62 vs.
95 days; P , 0.001).
A greater proportion of infants received a PCR test and at
a younger median age post-B+ (Table 1). However, post-B+,
13.5% of infants failed to receive a PCR test, and, of those
tested, 216 of 863 (25%) were tested after 2 months of age.
There was no change in the median time for delivery of results
to caregivers. A smaller proportion of infants tested were
diagnosed as HIV-infected post-B+ (all infants: 4.6% vs. 2.6%;
P = 0.03); the difference remained significant after including
only those tested at 4–12 weeks (4.7% vs. 2.3%; P = 0.01).
There was neither a change in the proportion of HIV-
infected infants started on ART [75% (24/32) vs. 77.3% (17/22);
P = 0.85] nor median age at ART initiation [19.7 weeks,
(interquartile range: 15.4–31.1) vs. 16 (interquartile range: 13.3–
17.9); P = 0.08].
Sensitivity analysis evaluating changes in outcomes
after excluding women already on ART at PMTCT enroll-
ment remained significant (see Appendix A, Supplemental
Digital Content, http://links.lww.com/QAI/A692).
Multivariate logistic regression, examining maternal
factors associated with failure to obtain an infant PCR test
post-B+, found that being newly diagnosed as HIV-infected
was marginally associated with failure and not starting ART
was significantly associated with failure while adjusting for
other covariates (Table 2). Enrolling in the second trimester,
compared with later enrollment, and starting ART after
enrollment were protective.
In the post-B+ cohort, we also examined the relation-
ship between maternal outcomes 6 months after ART
initiation and failure to obtain an infant PCR test. Of the
626 infants born to women newly initiating ART after
enrollment, 34 transferred out and were excluded leaving
592 infants in the analysis. Infant PCR completion rates
were significantly different by maternal outcome category:
(P , 0.0001). Compared with those whose mothers were
alive on ART at 6 months, those whose mothers were lost to
follow-up/died or stopped ART were much more likely to fail
to get an infant PCR (OR 14.7; 95% CI: 7.0 to 30.8) and
(OR 27.5; 95% CI: 10.9 to 69.4), respectively.
DISCUSSION
In this first study to carefully examine infant outcomes
postimplementation of Option B+ in Malawi, we found
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modest improvement along the infant PMTCT cascade.
There was a significant improvement in duration of maternal
ART predelivery and smaller proportion of infants testing
positive. However, ongoing challenges such as prompt
delivery of EID results to caregivers and timely infant ART
initiation remained.
There was a significant improvement in the duration of
maternal ART during pregnancy (median, 62 vs. 95 days) and
smaller proportion of infants with a positive PCR test on early
testing post-B+ (4.6% vs. 2.6%). The lower transmission may
be secondary to increased proportion of eligible women
receiving ART and longer duration of maternal ART during
pregnancy. This is reassuring preliminary evidence of B+’s
impact on MTCT through extended maternal ART coverage
and the impact of the ART scale-up in Malawi with
increasing numbers of women entering PMTCT on ART.
However, studies measuring population-level vertical trans-
mission post-B+ implementation are needed.27
Our study suggests modest improvements in the
uptake of infant HIV testing (82% vs. 86.5%) and younger
median age at testing (7.6 vs. 6.9 weeks) post-B+. With B+,
more women initiated ART and therefore may have been
more likely to bring their infants in for testing. The linked
mother–infant data enabled us to provide preliminary in-
sights on the impact of maternal ART outcomes on infant
PCR testing uptake post-B+. Women who were lost to
follow-up or died or stopped ART were much more likely to
fail to have a recorded infant PCR test. These findings
TABLE 1. Baseline Maternal Characteristics and Changes in Service Uptake in the Infant PMTCT Cascade Pre- and Post-
Implementation of Option B+






Infants born to women enrolled in the PMTCT
program
845 998 —
Gender male, n/N (%) 402/844 (47.6) 464/998 (46.5) 0.63
Characteristics of infants’ mothers
at program enrollment during
antenatal care
Median maternal age, yrs (IQR) 27.1 (23.9–31.0) 28.0 (24.2–31.8) 0.07
Trimester of pregnancy, n (%)
First 24 (2.8) 44 (4.4) ,0.0001
Second 449 (53.1) 627 (62.9) —
Third 372 (44.0) 326 (32.7) —
Missing data 0 1 —
HIV status at enrollment, n (%)
Already known to be HIV-infected 254 (30.2) 483 (48.4) ,0.0001
Newly diagnosed as HIV-infected 588 (69.8) 515 (51.6) —
Missing 3 0 —
Mom on ART at enrollment into PMTCT
program, n (%)
174/845 (20.6) 325/998 (32.6) ,0.0001
Maternal ART/ARVs for PMTCT Mom received ART/ARVs* for PMTCT, n (%) 801/845 (94.8) 951/998 (95.3) 0.62
Newly initiated ART/ARVs for PMTCT 627/671 (93.4) 626/673 (93.0) 0.76
New ART initiation 206/627 (32.9) 626/626 (100) ,0.0001
Days on ART before delivery among those
newly initiating, median (IQR)
62 (38–94) 95 (61–131) ,0.0001
Infant ARVs for PMTCT Infant received ARVs† for PMTCT, n/N (%) 817/845 (96.7) 957/998 (95.9) 0.37
Infant HIV DNA PCR testing,
transmission, and ART initiation
Infant received HIV DNA PCR test, n/N (%)‡ 693/845 (82.0) 863/998 (86.5) 0.01
Median weeks of age at time of test, (IQR) 7.6 (6.6–10.9) 6.9 (6.4–8.1) ,0.0001
PCR test result available, n/N (%) 691/693 (99.7) 860/863 (99.7) 1.00
Median weeks from test taken to result given
to caregiver, (IQR)
8 (4.7–10) 8 (4.3–10) 0.53
Of infants with positive PCR test, median
weeks of age at PCR test, (IQR)
7.5 (6.5–10.7) 6.9 (6.4–8.0) 0.32
Infants found have be HIV-infected at first PCR
(number positive/number of available first
PCR results), n/N (%)
32/691 (4.6) 22/860 (2.6) 0.03
PCR done at 4–12 wks of age, n/N (%) 26/549 (4.7) 18/793 (2.3) 0.01
HIV-infected infants started on ART, n/N (%) 24/32 (75.0) 17/22 (77.3) 0.85
Median weeks of age at ART initiation,
(IQR)
19.7 (15.4–31.1) 16 (13.3–17.9) 0.08
*Pre-B+, this included lifelong ART (stavudine-lamivudine-NVP) if CD4+ ,350 cells per cubic millimeter, or ZDV from 28 wks gestation to delivery + single-dose NVP at
delivery if CD4+ $350 cells per cubic millimeter. Post-B+, all HIV-infected pregnant women were automatically eligible for lifelong ART (tenofovir-lamivudine-efavirenz).
†Pre-B+, infants received single-dose NVP and ZDV for 1 week after birth. Post-B+, infants received NVP for 6 weeks after delivery.
‡During both observation periods, EID with DNA PCR testing on dried blood spot specimens was offered at $ 6 weeks of age.
ARVs, antiretroviral medications; IQR, interquartile range; NVP, nevirapine; ZDV, zidovudine.
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highlight the need for targeted efforts to better understand
and address women’s choices around engagement in care
and adherence to ART, as well as where and how infant care
is best delivered. Women starting ART after enrollment at
antenatal clinic (ANC) were more likely to get an infant
PCR test. This may indicate that women13 and infants by
extension may benefit from more time to prepare for ART
initiation and infant testing. However, additional research is
needed to explore if delayed initiation may be protective or
if women who delay are inherently different.
Despite the improvements in duration of maternal
ART, transmission, and timely EID uptake, we did not see
improvement along other critical points in the infant
cascade. A sizeable portion of infants failed to receive
a PCR test (13.5%) post-B+, and 25% were tested after 2
months of age. Furthermore, there was no change in the
median time to delivery of test results, proportion of infants
started on ART, or age at ART start, which remained at
a median of 16 weeks. There is increasing evidence that, for
some infants, ART initiation even by 12 weeks of age may
not adequately prevent disease progression or death.28
Delays in diagnosis because of late testing and slow
turnaround of results lead to late ART initiation and
subsequent increases in infant morbidity and mortality.17,29
There is a need to develop and evaluate strategies not only
for earlier identification of HIV-infected infants6 but more
rapid ART initiation to further reduce infant mortality.29
The study is limited in that it used a historical control
group. Because of the rapid and widespread scale-up of
Option B+ throughout the country, contemporary controls
were not available. Therefore, improvements in maternal
ART coverage predelivery and transmission post-B+ may
represent maturity of the ART, PMTCT, and EID programs
or may be secondary to other unknown contemporary
influences or epidemiologic trends. However, other than
training on the new national B+ protocols,8 service activities
were unchanged. Furthermore, we report data from large
urban health centers in Malawi within a CHW-supported
program with better outcomes pre-B+ than those reported
nationally. Therefore, generalizability to centers in rural
Malawi or with less support may be limited. Indeed, the
impact of B+ on EID uptake and infant ART initiation may
be more robust at sites with worse PMTCT uptake before
B+. Finally, this study is limited to early infant outcomes.
We can report on survival and final infant infection status
postweaning as the cohort matures.
This preliminary evidence suggests that post-B+ there
have been improvements in maternal ART coverage pre-
delivery, decreased proportion of infants testing HIV-
positive, and modest improvements in uptake and timing
of EID. However, despite these noteworthy successes,
additional strategies to increase EID testing coverage,
improve timely delivery of results, and expedite prompt
ART are still needed.





Adjusted OR of Failure
(95% CI)* (N = 976) P
Maternal age, yrs
,20 11/80 (13.8) 1.00 (ref) — 1.00 (ref) —
20+ 103/897 (11.5) 0.81 (0.42 to 1.59) 0.55 1.03 (0.49 to 2.17) 0.95
Trimester of pregnancy, n (%)
First 6/43 (14.0) 0.86 (0.34 to 2.13) 0.74 0.96 (0.36 to 2.59) 0.94
Second 57/613 (9.3) 0.54 (0.36 to 0.81) 0.003 0.55 (0.36 to 0.83) 0.005
Third 51/320 (15.9) 1.00 (ref) — 1.00 (ref) —
Missing data 1 — — — —
HIV status at enrollment, n (%)
Already known to be HIV-infected 44/473 (9.3) 1.00 (ref) — 1.00 (ref) —
Newly diagnosed as HIV-infected 70/504 (13.9) 1.57 (1.05 to 2.35) 0.03 1.94 (0.89 to 4.23) 0.09
Time to maternal ART initiation
On ART before enrollment 30/320 (9.4) 1.00 (ref) — 1.00 (ref) —
Initiated the same day of enrollment 50/331 (15.1) 1.72 (1.06 to 2.78) 0.03 0.97 (0.47 to 2.03) 0.94
Initiated after the day of enrollment† 25/314 (8.0) 0.84 (0.48 to 1.46) 0.53 0.45 (0.20 to 1.01) 0.05
Did not start ART 9/12 (75.0) 28.99 (7.40 to 112.88) ,0.0001 18.59 (4.46 to 77.59) ,0.0001
Partner disclosure status at enrollment, n (%)*
Partner involved and disclosed 39/412 (9.5) 1.00 (ref) — 1.00 (ref) —
Partner involved, not disclosed 74/542 (3.7) 1.51 (1.00 to 2.28) 0.05 1.11 (0.60 to 2.08) 0.73
Partner not involved 1/23 (4.4) 0.44 (0.06 to 3.31) 0.42 0.41 (0.05 to 3.20) 0.40
The analysis was conducted among HIV-infected pregnant women with a recorded birth who were enrolled during the post-option B+ period. Those transferred out without PCR
testing were excluded.
All covariates were tested for entry into the multivariate model. No 2-way interaction was found in the multivariate logistic regression model using significance level of 0.05.
*Partner disclosed defined as partner having knowledge of maternal HIV status. Partner noninvolved defined as a partner who has died, or is otherwise separated from the mother.
Hosmer and Lemeshow goodness-of-fit: P = 0.93, supporting the model’s adequacy and no evidence of lack of fit.
†Among those who started ART after the day of enrollment, median to ART start was 23 (IQR: 7–53) days.
Bold P values are # to 0.05.
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